SNMN yields 2000000.00% · ABBV yields 3.06%● Live data
📍 SNMN pulled ahead of the other in Year 1
Combined, SNMN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SNMN + ABBV for your $10,000?
SNM Global Holdings, Inc., together with its subsidiaries, provides international south Asian media, entertainment, and marketing services with operations in the areas of publication, broadcast television, radio, Internet, film, television production, events, advertising, and marketing. The company publishes a weekly English language newspaper, The Indian Express North American Edition, comprising three regional editions in the United States and an edition in Canada; and Divya Bhaskar North American Edition, a weekly Gujarati language newspaper for the sub-ethnic Gujarati community in the United States and Canada, as well as has a marketing tie-up with the Telugu language newspaper, Telugu Times in North America. It also broadcasts INDIA PLUS on DIRECTV that offers news and current affairs programming for Indians in the United States; and operates as partner in the FM radio station for the south Asian community in North America. In addition, the company produces international television programming in the United States and India for south Asian TV networks; develops films for Bollywood and international markets; and produces proprietary events, such as CineMaya Media Group Indian American Achiever Awards, as well as events for clients. SNM Global Holdings, Inc. was formerly known as CineMaya Media Group, Inc. and changed its name to CineMaya Media Group, Inc. in November 2008. The company was founded in 2000 and is based in Miami, Florida with additional offices in Edison, New Jersey; Santa Clara, California; Toronto, Canada; Mumbai and Delhi, India; and Chicago, Illinois.
Full SNMN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.